Purpose: Respiratory syncytial virus (RSV) and influenza are important viral pathogens worldwide. Children, in particular, bear considerable burdens of morbidity and mortality associated with these viruses. There are limited therapeutic options for children infected with RSV or influenza. This review focuses on therapeutics for RSV and influenza that are currently under clinical investigation.
Methods: This study used a systematic approach to identify prospective therapeutics in clinical trials and briefly reviewed those that are currently available for use in adults and children.
Findings: Overall, we found 14 investigational drugs currently in clinical trials for RSV and 20 investigation drugs currently in clinical trials for influenza. These candidates range in development from Phase I to Phase III clinical trials.
Implications: Both RSV and influenza are targets for active therapeutic research, and promising candidates for both viruses are currently in clinical development.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.clinthera.2018.06.014 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Synthesis and Antiviral Evaluation of 5-(4-Aryl-1,3-butadiyn-1-yl)-uridines and Their Phosphoramidate Pronucleotides.
Molecules
December 2024
Institute of Organic and Analytical Chemistry (ICOA UMR 7311), CNRS, University of Orleans, F-45067 Orléans, France.
The emergence of RNA viruses driven by global population growth and international trade highlights the urgent need for effective antiviral agents that can inhibit viral replication. Nucleoside analogs, which mimic natural nucleotides, have shown promise in targeting RNA-dependent RNA polymerases (RdRps). Starting from protected 5-iodouridine, we report the synthesis of -substituted-(1,3-diyne)-uridines nucleosides and their phosphoramidate prodrugs.
View Article and Find Full Text PDFTwins with at least one with CHD and their immunisation status in direct comparison-are both twins complying with the German immunisation recommendations?
Cardiovasc Diagn Ther
December 2024
Department of Congenital Heart Disease and Pediatric Cardiology, German Heart Center Munich, Technical University of Munich, Munich, Germany.
Background: Patients with congenital heart defects (CHDs) are at higher risk for infectious diseases. This may partly be due to frequent hospital stays and the associated exposure to pathogens. This study aims to provide a comprehensive overview of immunisation coverage among twins in which at least one twin has CHD.
View Article and Find Full Text PDFImpact of RSVpreF vaccination on reducing the burden of respiratory syncytial virus in infants and older adults.
Nat Med
January 2025
Center for Infectious Disease Modeling and Analysis, Yale School of Public Health, New Haven, CT, USA.
Respiratory syncytial virus (RSV) causes a substantial health burden among infants and older adults. Prefusion F protein-based vaccines have shown high efficacy against RSV disease in clinical trials, offering promise for mitigating this burden through maternal and older adult immunization. Employing an individual-based model, we evaluated the impact of RSV vaccination on hospitalizations and deaths in 13 high-income countries, assuming that the vaccine does not prevent infection or transmission.
View Article and Find Full Text PDFBurden of disease of respiratory syncytial virus in older adults and adults considered at high risk of severe infection.
Can Commun Dis Rep
January 2025
Public Health Agency of Canada, Ottawa, ON.
Background: Availability of new vaccines for adults has increased interest in understanding Canada's respiratory syncytial virus (RSV) burden in older adults and adults considered at high risk of severe infection.
Objective: To characterize the burden of RSV disease in Canada by joint analysis of the published literature and hospitalization data from a healthcare administrative database.
Methods: Electronic databases of published literature were searched to identify studies and systematic reviews reporting data on outpatient visits, hospitalizations, intensive care unit (ICU) admissions and deaths associated with RSV infection in adults.
Attitude to RSV Vaccination Among a Cohort of Pregnant Women in Jordan: A Cross-Sectional Survey Study.
Health Sci Rep
January 2025
Department of Obstetrics & Gynecology, School of Medicine The University of Jordan Amman Jordan.
Background And Aims: The recently approved maternal vaccination against respiratory syncytial virus (RSV) can reduce its burden among infants. However, vaccine hesitancy/resistance can undermine the beneficial impact of RSV vaccination. The aim of this study was to assess the willingness of pregnant women in Jordan to receive RSV vaccination and its associated determinants.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!